慢性肾衰血透患者血清和尿中IL-8的变化

目的：了解慢性肾衰（CRF）状态及血液透析（HD）环境下患者血清和尿中白细胞介素一8（IL-8）含量的变化规律和IL-8与残余肾功能（RRF）的关系．方法：采用双抗体夹心ELISA法检测25例CRF维持性血透患者和21例CRF非透析患者及26例健康体检者血清和尿中IL-8的含量．结果：CRF患者非HD组和HD组呶清和尿中IL-8的含量均显著高于正常对照组（P＜O．01）;HD组患者透析结束时血清和尿中IL-8的含量明显高于透析前（P＜O．01）。血透结束后48h较血透结束时降低，但仍高于透析前，差别个显著（P＞0．05）;CRF患者非HD组与HD组血泊和尿中IL-8的含量均与Scr无明星相关性计（r＝-0．34．P＞O．05和r＝-0．06．P＞0．05）;HD组中无尿患者（尿量＜400mL／d）血清和尿中IL-8的含量明显高于有尿患者（尿量＞400mL／d）（P＜O．05）．且患者血清和尿中IL-8的含量与尿量成显著负相关（r=一0．467，P＜0．05和r=一0．548．P＜O.05）结论CRF状态和HD环境下都存在严重的免疫炎症反应．且HD对IL-8的产生有明显的诱导作用，此可能为CRF维持性血透患者RRF进一步受损的主要原因之一。

Graves病患者治疗前后细胞因子的变化

目的 测定 Graves病 (GD)患者血清肿瘤坏死因子(TNF- α)、白细胞介素 1(IL- 1)、白细胞介素 2 (IL- 2 )、白细胞介素 6 (IL - 6 )的水平及在抗甲状腺药物治疗过程中的变化 .方法 32例 GD患者在确诊时、治疗约 6周和 6月时用放射免疫法测定血清 TNF- α,IL- 1,IL- 2 ,IL- 6 ,TSH,TT3,TT4的水平 . 2 5例年龄与性别相匹配的健康志愿者作为正常对照 .结果 1与正常对照组相比 ,TNF- α在缓解前明显降低 (1.0 1± 0 .18)μg· L- 1 (P<0 .0 0 1) ,缓解中开始升高(1.2 7± 0 .19)μg· L- 1 ,缓解后继续升高 (1.42± 0 .17)μg·L- 1 ,但仍低于正常对照组 (1.6 9± 0 .15 ) μg· L- 1 ;IL- 1,IL-6在缓解前明显升高 (0 .39± 0 .0 9)μg· L- 1 ,(1.79± 0 .2 1)μg· L- 1 (P<0 .0 1) ,缓解中即降低 (0 .2 8± 0 .0 7) μg· L- 1 ,(1.5 1± 0 .19) μg· L- 1 ,缓解后 (0 . 2 1± 0 . 0 7) μg· L- 1 ,(1.40± 0 .2 1)μg· L- 1 与正常对照组 (0 .2 0± 0 .0 6 )μg· L- 1 ,(1.41± 0 .16 )μg· L- 1 无显著差异 ;IL - 2在缓解前明显降低(4 .2± 1.2 ) μg· L- 1 (P<0 .0 1) ,缓解中即升高 (5 .0± 1.7)μg· L - 1 ,缓解后 (6 .1± 2 .7) μg· L- 1与正常对照组 (6 .3± 2 .3)μg· L- 1无显著?

Effects of Composite Xinyi Aerosol (复方辛夷雾化剂) on Asthma Related Cytokines in Serum and Sputum of Patients with Bronchial Asthma

Objective: To observe the therapeutic effect of composite Xinyi ae rosol (复方辛夷雾化剂, XYA) in treating asthma and its influence on asthma relat ed cytokines in serum and sputum of patients with mild or moderate bronchial ast hma.Methods: Sixty patients were divided randomly into the treated gr oup and the control group, 30 in each group. They were treated with XYA and Salb utamol aerosol (SA) respectively by spray inhalation once a day for seven days a s one therapeutic course to observe the antiasthmatic effect of the treatment. Changes of lung function and the levels of tumor necrosis factor α (TNF-α) , interleukine-2 receptor (IL-2R) and interleukine-8 (IL-8) in serum and sputum were observed before and after treatment using enzyme linked immunos orbent assay (ELISA). Levels of TNF-α, IL-2R andIL-8 in the sputum of part of the patients in the treatment group were also observed.Results: In the treated group, 6 patients had the asthma clinica lly controlled after treatment, 12 were markedly alleviated, 9 alleviated and 3 remained unchanged, while in the control group, the respective numbers were 4, 6 , 15 and 5. The controlled-markedly effective rate of XYA was 60.0%, which wa s significantly better than that of SA (33.3%, P <0.05). The one second forc ed expiratory volume percent (FEV1%) and peek expiratory flow rate (PEFR) improv ed significantly and the levels of TNF-α, IL-2R and IL-8 in serum decr eased noticeably in both groups after treatment ( P <0.05 or P <0.01), but the improvement in the treated group was more significant as compared with tho se in the control group ( P <0.05). The levels of TNF-α, IL-2R and IL -8 in sputum considerably lowered also after XYA treatment ( P <0.01).Conclusion: XYA could regulate the related cytokines in patient s with mild or moderate bronchial asthma, and reduce the releasing of inflammato ry factors, which is consistent with the improvement of lung functions, so as to ease the airway inflammation chiefly exhibited as cell infiltration in bron chi.